Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases, and
The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a
non-profit organization dedicated to finding a cure for Parkinson’s
disease (PD), today announced a research project to accelerate
research on genetic risk factors associated with PD, specifically
targeting the role of variants in the GBA (glucosylceramidase beta)
gene.
PD is a devastating neurodegenerative disease affecting over 10
million people worldwide, with many cases being linked to genetic
factors. Recent research has identified the GBA gene as a
significant genetic risk factor for PD, which could shed new light
on potential biological pathways for the development of effective
therapies.
The research project will leverage CENTOGENE’s expertise in rare
genetic and neurodegenerative diseases, drawing on diverse
multiomic data in the CENTOGENE Biodatabank. The biodatabank
currently contains more than 800,000 patients representing over 120
highly diverse countries, including over 15,000 Parkinson’s disease
datasets from the Company’s ROPAD Study, the world’s largest
observational study on PD genetics. In working with MJFF, the aim
of the research is to establish a deeper understanding of the
relationship between specific GBA gene variants and PD.
“Understanding the different factors that actually cause
Parkinson’s disease are critical to advancing treatments and
ultimately finding a cure,” said Shalini Padmanabhan, Vice
President, Discovery & Translational Research at The Michael J.
Fox Foundation for Parkinson’s Research. “This project with
CENTOGENE will play a pivotal role in our global efforts to better
understand the genetic factors of Parkinson's, leveraging their
robust multiomic datasets that they have built over the past 15
years. We are committed to working together to truly drive the most
comprehensive understanding of this disease and accelerate the
development of life-saving treatments for patients worldwide.”
“The Michael J. Fox Foundation is an inspirational leader in
Parkinson’s disease research. By working with them, we aim to
accelerate research into specific risk factors that may help us
better diagnose, understand, and treat this debilitating disease,
which affects several million patients worldwide,” said Prof. Peter
Bauer, Chief Medical & Genomic Officer at CENTOGENE. “By
combining MJFF’s extensive expertise and resources with our deep
understanding of the links between rare and neurodegenerative
diseases, we will be able to generate pivotal multiomic insights
into the role of specific variants in the GBA gene. By providing a
more complete understanding of the way that the GBA gene interacts
with multiple biological pathways, we can elucidate targets that
can be used to develop more precise disease-modifying therapeutics
for Parkinson’s patients in the future.”
About GBA-Associated
Parkinson’s Disease
GBA-Associated Parkinson's disease (PD) is characterized by
specific variants in the GBA (glucosylceramidase beta) gene and has
been identified as one of the most common genetic risk factors for
PD. Variants in the GBA gene impair the body's ability to break
down certain fats, leading to a buildup of harmful substances in
nerve cells. This accumulation, as well as potentially other
independent consequences of GBA dysfunction, can contribute to the
development of PD symptoms, which resemble the motor symptoms of
idiopathic PD, such as tremors, stiffness, and bradykinesia.
Recognizing the connection between GBA variants and PD is crucial
for both diagnosis and potential targeted therapies, emphasizing
the importance of ongoing research and clinical investigations in
this area, as there's currently no cure for PD.
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
800,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 285 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “is set to,” “potential,” “predict,” “objective” and
similar expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, changes in our mix of customers and partners and
their order practices with respect to our products and solutions,
our reliance on third parties and collaboration partners, including
our ability to manage growth, execute our business strategy and
enter into new client relationships, our dependency on the rare
disease industry, our ability to manage international expansion,
our reliance on key personnel, our reliance on intellectual
property protection, fluctuations of our operating results due to
the effect of exchange rates, our ability to streamline cash usage,
our continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, and our
ability to continue as a going concern, or other factors. For
further information on the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on May 16, 2023, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and CENTOGENE
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations
IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024